Researchers recently found that the pharmacokinetic properties of vesicular monoamine transporter 2 inhibitors may play a role in the treatment of tardive dyskinesia. Healio Neurology spoke with Eiry W. Roberts, MD, Neurocrine Biosciences chief medical office…